Tuberculosis test kit Xpert® MTB/XDR

laboratorymolecular

Simplifying TB drug susceptibility testing utilizing increased multiplexing capability with 10 color GeneXpert® technology The Need In 2022, only 43% of the total estimated multidrug-resistant Tuberculosis (MDR-TB) incident cases were diagnosed and enrolled on treatment regimen1 Only 47% of the total notified MDR-TB cases were tested for resistance to fluoroquinolones1 Increase access to rapid and extended drug resistance profiling for all TB-positive cases to rule out MDR/pre-XDR^ TB2 The Solution The Xpert MTB/XDR test enables rapid molecular DST. When combined with the frontline Xpert MTB/RIF Ultra test, it detects mutations associated with resistance to isoniazid (INH), fluoroquinolones (FLQ), second-line injectable drugs (SLIDs), and ethionamide (ETH) in a single test. Fast time to result for molecular DST Same easy-to-use process as the Xpert MTB/RIF Ultra test Run on existing GeneXpert® platforms equipped with 10-color modules The Impact Upfront molecular DST for TB‑positive cases supports timely treatment planning Helps supports expanded access to drug‑resistance testing for MDR and pre‑XDR TB.3 The Xpert MTB/XDR assay provides the capability to differentiate between high and low-level resistance to INH and FLQ, which which provides additional information that may support resistance interpretation alongside clinical findings.4